These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 30159866)

  • 1. Place of neurosteroids in the treatment of status epilepticus.
    Rossetti AO
    Epilepsia; 2018 Oct; 59 Suppl 2():216-219. PubMed ID: 30159866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacotherapy for Refractory and Super-Refractory Status Epilepticus in Adults.
    Holtkamp M
    Drugs; 2018 Mar; 78(3):307-326. PubMed ID: 29368126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGE-102: a novel therapy for refractory status epilepticus.
    Reddy K; Reife R; Cole AJ
    Epilepsia; 2013 Sep; 54 Suppl 6():81-3. PubMed ID: 24001082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intramuscular allopregnanolone and ganaxolone in a mouse model of treatment-resistant status epilepticus.
    Zolkowska D; Wu CY; Rogawski MA
    Epilepsia; 2018 Oct; 59 Suppl 2(Suppl 2):220-227. PubMed ID: 29453777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric super-refractory status epilepticus treated with allopregnanolone.
    Broomall E; Natale JE; Grimason M; Goldstein J; Smith CM; Chang C; Kanes S; Rogawski MA; Wainwright MS
    Ann Neurol; 2014 Dec; 76(6):911-5. PubMed ID: 25363147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurosteroids as Novel Anticonvulsants for Refractory Status Epilepticus and Medical Countermeasures for Nerve Agents: A 15-Year Journey to Bring Ganaxolone from Bench to Clinic.
    Reddy DS
    J Pharmacol Exp Ther; 2024 Jan; 388(2):273-300. PubMed ID: 37977814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroactive steroids for the treatment of status epilepticus.
    Rogawski MA; Loya CM; Reddy K; Zolkowska D; Lossin C
    Epilepsia; 2013 Sep; 54 Suppl 6(0 6):93-8. PubMed ID: 24001085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous ganaxolone for the treatment of refractory status epilepticus: Results from an open-label, dose-finding, phase 2 trial.
    Vaitkevicius H; Ramsay RE; Swisher CB; Husain AM; Aimetti A; Gasior M
    Epilepsia; 2022 Sep; 63(9):2381-2391. PubMed ID: 35748707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic treatment of status epilepticus.
    Trinka E; Höfler J; Leitinger M; Rohracher A; Kalss G; Brigo F
    Expert Opin Pharmacother; 2016; 17(4):513-34. PubMed ID: 26629986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ganaxolone treatment for epilepsy patients: from pharmacology to place in therapy.
    Lattanzi S; Riva A; Striano P
    Expert Rev Neurother; 2021 Nov; 21(11):1317-1332. PubMed ID: 33724128
    [No Abstract]   [Full Text] [Related]  

  • 11. Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit.
    Rohracher A; Höfler J; Kalss G; Leitinger M; Kuchukhidze G; Deak I; Dobesberger J; Novak H; Pilz G; Zerbs A; Trinka E
    Epilepsy Behav; 2015 Aug; 49():354-8. PubMed ID: 25962657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The synthetic neuroactive steroid SGE-516 reduces status epilepticus and neuronal cell death in a rat model of soman intoxication.
    Althaus AL; McCarren HS; Alqazzaz A; Jackson C; McDonough JH; Smith CD; Hoffman E; Hammond RS; Robichaud AJ; Doherty JJ
    Epilepsy Behav; 2017 Mar; 68():22-30. PubMed ID: 28109985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stiripentol in refractory status epilepticus.
    Grosenbaugh DK; Mott DD
    Epilepsia; 2013 Sep; 54 Suppl 6():103-5. PubMed ID: 24001087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Super-Refractory Status Epilepticus.
    Cuero MR; Varelas PN
    Curr Neurol Neurosci Rep; 2015 Nov; 15(11):74. PubMed ID: 26404727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Super-Refractory Status Epilepticus: Report of a Case and Review of the Literature.
    Lapenta L; Frisullo G; Vollono C; Brunetti V; Giannantoni NM; Sandroni C; Di Lella G; Della Marca G
    Clin EEG Neurosci; 2015 Oct; 46(4):335-9. PubMed ID: 25258428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is Favorable Outcome Possible After Prolonged Refractory Status Epilepticus?
    Alvarez V; Drislane FW
    J Clin Neurophysiol; 2016 Feb; 33(1):32-41. PubMed ID: 26840875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous ganaxolone in pediatric super-refractory status epilepticus: A single hospital experience.
    Singh RK; Singh R; Stewart A; Van Poppel K; Klinger S; Hulihan J; Van Heusen H; Vaitkevicius H; Gasior M
    Epilepsy Behav Rep; 2022; 20():100567. PubMed ID: 36325100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benzodiazepine-refractory status epilepticus: pathophysiology and principles of treatment.
    Niquet J; Baldwin R; Suchomelova L; Lumley L; Naylor D; Eavey R; Wasterlain CG
    Ann N Y Acad Sci; 2016 Aug; 1378(1):166-173. PubMed ID: 27392038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refractory and super-refractory status epilepticus in adults: a 9-year cohort study.
    Delaj L; Novy J; Ryvlin P; Marchi NA; Rossetti AO
    Acta Neurol Scand; 2017 Jan; 135(1):92-99. PubMed ID: 27080243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary results of the global audit of treatment of refractory status epilepticus.
    Ferlisi M; Hocker S; Grade M; Trinka E; Shorvon S;
    Epilepsy Behav; 2015 Aug; 49():318-24. PubMed ID: 25952268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.